Dewpoint Therapeutics

Dewpoint Therapeutics company information, Employees & Contact Information

Dewpoint is the first company to apply an emerging understanding of biomolecular condensates to drug discovery. Dewpoint develops drugs for the vast range of conditions that are regulated by condensates or arise from the dysfunction of condensates. Dewpoint currently has multiple programs across an ambitious pipeline spanning oncology, neurodegeneration, cardiopulmonary, and virology indications, and collaborations with leading global academic and pharmaceutical partners, including Bayer, Novo Nordisk, Evotec and Chemify. Dewpoint scientists work in Boston, Dresden and Frankfurt to translate condensate biology into breakthrough treatments for diseases previously considered untreatable.  Please be aware of the potential for scams and fraudulent recruitment activity from individuals claiming to represent Dewpoint Therapeutics. Dewpoint never conducts its interviewing or recruiting processes via messaging apps, freelance sites, or social media platforms (i.e., Facebook, WhatsApp, Telegram, Signal, etc.) except for LinkedIn Recruiter. All communication originating from the Dewpoint team, including those communications relating to any job opportunities, comes through an official Dewpoint email address ending in “@dewpointx.com, the official Dewpoint LinkedIn account, or from the People & Culture team.” We strongly advise you not to provide any personal information if you receive a suspicious inquiry or job offer through any medium other than these official Dewpoint email addresses. Please be further advised that Dewpoint does not accept unsolicited resumes from external recruitment firms. If you suspect any fraudulent activity or misrepresentation in connection with a Dewpoint job opportunity, please report it immediately to contact@dewpointx.com.

Company Details

Employees
105
Founded
-
Address
451 D Street, Suite 104,germany
Email
in****@****ntx.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Boston, MA
Looking for a particular Dewpoint Therapeutics employee's phone or email?

Dewpoint Therapeutics Questions

News

Dewpoint Therapeutics partners with Novo Nordisk to explore the field of biomolecular condensates to treat insulin resistance and diabetes progression - PR Newswire

Dewpoint Therapeutics partners with Novo Nordisk to explore the field of biomolecular condensates to treat insulin resistance and diabetes progression PR Newswire

Dewpoint Therapeutics and Mitsubishi Tanabe Pharma Corporation Enter Research Collaboration to Advance Small Molecule Condensate Modulator for ALS - Yahoo Finance

Dewpoint Therapeutics and Mitsubishi Tanabe Pharma Corporation Enter Research Collaboration to Advance Small Molecule Condensate Modulator for ALS Yahoo Finance

Dewpoint Therapeutics Announces Presentation at AACR-NCI-EORTC 2025 - GlobeNewswire

Dewpoint Therapeutics Announces Presentation at AACR-NCI-EORTC 2025 GlobeNewswire

Dewpoint Therapeutics Announces an Open IND for First-in-Class Condensate Modulator DPTX3186 for Wnt-Driven Cancers - Yahoo Finance

Dewpoint Therapeutics Announces an Open IND for First-in-Class Condensate Modulator DPTX3186 for Wnt-Driven Cancers Yahoo Finance

Metabolic switch from fatty acid oxidation to glycolysis in knock‐in mouse model of Barth syndrome - EMBO Press

Metabolic switch from fatty acid oxidation to glycolysis in knock‐in mouse model of Barth syndrome EMBO Press

Dewpoint Therapeutics Partners with Chemify to Apply Groundbreaking Chemistry AI to Radically Accelerate the Discovery of Molecules Targeting Cancer and Neurodegeneration - PR Newswire

Dewpoint Therapeutics Partners with Chemify to Apply Groundbreaking Chemistry AI to Radically Accelerate the Discovery of Molecules Targeting Cancer and Neurodegeneration PR Newswire

Bayer and Dewpoint Therapeutics sign Licensing Agreement for Heart Disease Program - GlobeNewswire

Bayer and Dewpoint Therapeutics sign Licensing Agreement for Heart Disease Program GlobeNewswire

Dewpoint Therapeutics Closes Series D Financing to Advance First-in-Class Condensate Modulator (c-mod) into Clinical Development for Gastric Cancer - Yahoo Finance

Dewpoint Therapeutics Closes Series D Financing to Advance First-in-Class Condensate Modulator (c-mod) into Clinical Development for Gastric Cancer Yahoo Finance

Dewpoint Therapeutics Announces DPTX3496 as a Development Candidate for the Treatment of Colorectal, Breast, and Lung Cancers - Yahoo Finance

Dewpoint Therapeutics Announces DPTX3496 as a Development Candidate for the Treatment of Colorectal, Breast, and Lung Cancers Yahoo Finance

Top Dewpoint Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant